Compare AFL & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFL | TAK |
|---|---|---|
| Founded | 1955 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8B | 56.6B |
| IPO Year | 1994 | N/A |
| Metric | AFL | TAK |
|---|---|---|
| Price | $113.83 | $17.82 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $110.18 | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 3.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 2.16% | ★ 2.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.82 | N/A |
| Revenue | ★ $17,164,000,000.00 | N/A |
| Revenue This Year | N/A | $0.38 |
| Revenue Next Year | $1.61 | $1.02 |
| P/E Ratio | ★ $16.58 | $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $96.95 | $12.99 |
| 52 Week High | $119.32 | $18.90 |
| Indicator | AFL | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 44.02 |
| Support Level | $106.07 | $17.65 |
| Resistance Level | $115.84 | $18.74 |
| Average True Range (ATR) | 2.08 | 0.26 |
| MACD | 0.54 | -0.08 |
| Stochastic Oscillator | 97.75 | 15.16 |
Aflac Inc offers supplemental health insurance and life insurance in the United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling the majority of its policies directly to consumers at their places of work, and also reaches out to its customers outside of their worksite through digital mediums. The company has two reportable business segments: Aflac Japan, which generates the maximum revenue, and Aflac U.S.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.